RxDoctor Payments Data

Kriti Bhagat, OD

Optometrist · Providence, RINPI 1427464510

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (40.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 50.9% of the total. 2025 is the largest year on record at $124,955, 4.3 times the $29,079 reported in 2019. Among optometrist clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$342,681in general payments, 2019–2025

Across 657 payments — averaging $521.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$174K
  • Alcon$140K
  • Biotissue Holdings Inc.$13K
  • Glaukos Corporation$9K
  • Coopervision Inc.$5K
  • Dompe US, Inc.$321
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$129,93038%
  • Speaking & faculty fees$139,27541%
  • Travel & lodging$58,44517%
  • Food & beverage$14,8244%
  • Entertainment$2080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$342,681 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$27,927
Medicare patients
75
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$207

Paid to pharmacies, not to this prescriber.

Other optometrist in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →